Skip to content
Peptide research

Mod GRF 1-29

Also known as Modified GRF · CJC-1295 no DAC · CJC-1295 without DAC
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A modified GHRH fragment that triggers pulsatile growth hormone release. The case is mostly mechanistic: preserved pulsatility and GHRP synergy have moderate support; claimed gains in body composition and sleep are low or speculative. Human safety data are minimal, and the resulting IGF-1 rise carries an unresolved, theoretical tumor concern. Not FDA-approved; most supply consists of unregulated products sold online.

Read Full record

Studied uses & evidence

Studied uses(5)

  • Dose-dependent increase in growth hormone levels

    Speculative

    Sustained multi-day GH rise is documented for CJC-1295 with DAC, not for Mod GRF 1-29.

  • Preservation of natural GH pulsatility (unlike exogenous GH injection)

    Medium

    Mechanistically expected from the GHRH-analog class; not directly measured for this specific compound.

  • Synergistic GH release with GHRPs (Ipamorelin, GHRP-6)

    Medium

    Human trials show greater GH release combining GHRH and GHRP-6, mostly in patient populations.

Evidence limits

Evidence Level
Limited Evidence

Direct clinical trial data for tetrasubstituted Mod GRF 1-29 is limited. The strongest evidence comes from the CJC-1295 (with DAC) RCTs showing sustained GH/IGF-1 elevation in healthy adults. Sermorelin (unmodified GRF 1-29) had sufficient clinical data for prior FDA approval. The specific tetrasubstituted form is widely used based on GHRH-class pharmacology and mechanistic rationale, with substantial anecdotal and clinical practice evidence but limited published controlled trials of the exact compound.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Risk summary(5)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Injection site reactions (redness, swelling, pain)

    High
  • Flushing and warmth

    Low
  • Water retention and joint stiffness

    Moderate
  • Potential impact on blood glucose regulation

    Moderate
  • Theoretical tumor growth promotion (via IGF-1 elevation)

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.